Patients for Thrombolysis
PE confirmed (n = 1880) (%) PE not confirmed (n = 528) (%) Symptoms Dyspnea 50 51 Pleuritic chest pain 39 28 Substernal chest pain 15 17 Syncope 6 6 Unilateral leg pain…
Thrombolysis in Special Situations
Fig. 8.1 Fig. 8.2 Fig. 8.3 Fig. 8.4 Table 8.1 Association between in-transit thrombus and embolic events Type Number of patients Associated to DVT (%) Associated to PE (%)…
Mechanisms of Thrombosis
Abnormal vessel walla Endothelial dysfunction characterized by endothelial cell activation (due to hypoxia, distension, and neurohormonal activation), increased expression of platelet/monocyte adhesion, tissue factor, von Willebrand factor, and thrombin; decreased…
Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents
Fig. 2.1 The structure of the fibrinolytic system is shown in this fig. It is possible to observe those plasminogen activators, plasminogen activator inhibitor-1, plasminogen, plasmin, and α2-antiplasmin role in…
Anticoagulation as Adjunctive Treatment and One-Hour Alteplase Infusion
Fibrinolytic regimen evaluation Variable Pre n = 40 (%) Post n = 40 (%) p Right ventricular sound 96 5 <0.0001 Shock 15 0 <0.0001 Respiratory rate 33.5 ± 5.7 25.0 ± 4.4 <0.0001 Cardiac rate 108.9 ± 13.1 94.4 ± 8.9…
Thrombolytic Therapy: Evidence-Based Results from Multicenter Control Trials
Years Author Number of patients 1970–2000 UPETSG (1970) 160 Tibbutt et al. (1974) 30 Ly et al. (1978) 25 Marini et al. (1988) 30 Levine et al. (1990) 58 PIOPED…
Current Guidelines and Recommendations for Thrombolysis Use in Pulmonary Embolism
Level A: Multiple populations evaluated. Data derived from multiple randomized clinical trials or meta-analyses Level B: Limited populations evaluated. Data derived from a single randomized trial or nonrandomized studies Level…
Thrombolysis in Pulmonary Embolism
Fig. 7.1 Modified of C Jerjes Sanchez y cols. Ischemic cascade that are generated from a massive PE over the right ventricle, and the phenomena that can increase or reduce…
